:

Parkinson’s disease in the NAKO: prevalence, functional limitations and risk of death

An analysis of the German National Cohort (NAKO) examined the prevalence, incidence, functional limitations and mortality among study participants with medically confirmed or probable Parkinson’s disease over a period of five years. The analysis revealed that those affected were, on average, older, more likely to be male and had a higher burden of comorbidities. Compared with people without Parkinson’s, the risk of death was around four times higher among those with Parkinson’s.

A research team led by the University of Münster analysed data from around 204,000 participants in the German National Cohort (NAKO). The researchers determined the proportion of people who had Parkinson’s disease at the time of the first NAKO examination between 2014 and 2019 (prevalence), as well as the number of new cases during the subsequent period from 2019 to 2024 (incidence).

As it was not possible to carry out a specialist neurological examination in a cohort as large as NAKO, three methodological approaches were used to determine the prevalence of Parkinson’s syndrome: self-reported information from participants, medically billed diagnoses, and a classification algorithm based on self-reported information and details of medication. Based on prescribed medication, in addition to information on the duration of the condition, an assessment was made as to whether a person definitely or probably had Parkinson’s disease. The analysis took into account active ingredients typically used to treat Parkinson’s disease.

Using this algorithm, the prevalence was 0.13 per cent. This means that, of the total of 204,273 people examined, 272 had been diagnosed with Parkinson’s disease according to this criterion. By contrast, the prevalence based on medical billing diagnoses was approximately 2 to 2.5 times higher. The incidence, based on self-reported data, was 0.13 per cent over an average observation period of 4.8 years. People with Parkinson’s had an approximately four times higher risk of death compared with those without Parkinson’s.

The analysis also showed that people with medically confirmed or probable Parkinson’s disease were, on average, older, and that men were affected more frequently than women. Cardiovascular comorbidities, such as high blood pressure, were more common in people with Parkinson’s disease, as was depression. “The latter is consistent with the recognised role of depressive symptoms as a non-motor symptom and a possible early manifestation of Parkinson’s disease. Other chronic conditions and multimorbidity were also observed more frequently in the group of people with Parkinson’s, indicating a higher overall burden of disease,” explains Prof. Dr Klaus Berger, Head of the Institute of Epidemiology and Social Medicine at the University of Münster. “Our data also confirm the impact of Parkinson’s disease on mortality and activities of daily living.”

About Parkinson’s disease

Parkinson’s disease is a progressive neurodegenerative disorder. The loss of dopamine-producing nerve cells leads to symptoms such as slowed movement, muscle stiffness, tremors at rest and balance problems.  In Germany, around 295,000 people were living with a diagnosed case of Parkinson’s disease in 2022. The prevalence increases significantly with age and stands at around 1.4 per cent among people aged 65 and over. [1]

[1] RKI – Journal of Health Monitoring – Die Parkinsonkrankheit – Prävalenz, Trends und regionale Verteilung in Deutschland. Eine Auswertung auf Basis von GKV-Routinedaten

More information

Original publication

Berger K, Karch A, Lill CM, et al. A comprehensive assessment of lifecourse and mortality of Parkinson’s disease in the German National Cohort. npj Parkinson’s Disease. 2026;12:156. doi:10.1038/s41531-026-01446-0.

Visit the website of the Institute of Epidemiology and Social Medicine at the University of Münster

Press contact:

Dr. Friederike Fellenberg
NAKO Gesundheitsstudie
Head of Project and Science Communication
Am Taubenfeld 21/2
69123 Heidelberg
Germany
Phone.: +49 6221 42620-62
E-mail: friederike.fellenberg@nako.de

German National Cohort (NAKO)

The German National Cohort (NAKO Gesundheitsstudie) is the largest long-term population study in Germany. Since 2014, over 205,000 randomly selected people have been medically examined and asked about their lifestyle habits in 18 study centres. At the beginning of the study, the participants were aged between 20 and 69.

The German National Cohort (NAKO) is a prospective epidemiological cohort study. The researchers observe a large group, a so-called cohort, of healthy, ill or formerly ill people over a long period of time. The aim is to use scientific analyses of the participants’ data to investigate the frequency and causes of common diseases such as cancer, diabetes or cardiovascular diseases, to identify risk factors and to show ways of effective prevention and early detection.

The research project is supported by 26 organisations. Scientists from universities, the Helmholtz Association, the Leibniz Association and other research institutes in Germany are working together in a nationwide network. The study is being carried out by the NAKO e.V. association. It is financed by public funds from the Federal Ministry of Research, Technology and Space (BMFTR), the Helmholtz Association and the participating federal states.